Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
Best practices for grounding brand decision-making in insights
In today’s evolving pharmaceutical landscape, harnessing the power of insights is more critical than ever. Integrating primary, secondary, and analytical...